The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

Marchion, Douglas

146 - Poster Session A
The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

Saturday, March 22, 2014: 10:05 AM

West Exhibit Hall (Tampa Convention Center)

D. Marchion¹, Y. Xiong¹, R. Ismail-Khan¹, F. Abbasi¹, N. Bou Zgheib², I. Ramirez², S. H. Bush², A. Hakam¹, P. L. Judson Lancaster¹ and J. M. Lancaster¹
¹H. Lee Moffitt Cancer Center, Tampa, FL, ²University of South Florida College of Medicine, Tampa, FL

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

146 - Poster Session A
The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

146 - Poster Session A The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

146 - Poster Session A
The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome